179 related articles for article (PubMed ID: 7689728)
1. Finasteride: the first 5 alpha-reductase inhibitor.
Sudduth SL; Koronkowski MJ
Pharmacotherapy; 1993; 13(4):309-25; discussion 325-9. PubMed ID: 7689728
[TBL] [Abstract][Full Text] [Related]
2. Finasteride: a 5 alpha-reductase inhibitor.
Steiner JF
Clin Pharm; 1993 Jan; 12(1):15-23. PubMed ID: 7679063
[TBL] [Abstract][Full Text] [Related]
3. Finasteride for benign prostatic hyperplasia.
Hasinski S; Miller JL; Rose LI
Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
[TBL] [Abstract][Full Text] [Related]
4. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
[TBL] [Abstract][Full Text] [Related]
5. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
J Androl; 1991; 12(6):372-5. PubMed ID: 1722792
[TBL] [Abstract][Full Text] [Related]
6. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
7. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
8. Finasteride for benign prostatic hypertrophy.
Med Lett Drugs Ther; 1992 Sep; 34(878):83-4. PubMed ID: 1380630
[No Abstract] [Full Text] [Related]
9. New options for patients with benign prostatic hyperplasia.
Ellenberger B
CMAJ; 1993 Feb; 148(4):543-7. PubMed ID: 7679313
[No Abstract] [Full Text] [Related]
10. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
11. Thoughts on finasteride for benign prostatic hyperplasia.
Anand A
Am Fam Physician; 1993 Sep; 48(4):582, 588. PubMed ID: 7691035
[No Abstract] [Full Text] [Related]
12. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
Stoner E
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
[TBL] [Abstract][Full Text] [Related]
13. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
14. Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Brown CT; Nuttall MC
Int J Clin Pract; 2003 Oct; 57(8):705-9. PubMed ID: 14627182
[TBL] [Abstract][Full Text] [Related]
15. Role of 5 alpha-reductase inhibitors in the treatment of advanced prostatic carcinoma.
Gormley GJ
Urol Clin North Am; 1991 Feb; 18(1):93-8. PubMed ID: 1846988
[TBL] [Abstract][Full Text] [Related]
16. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
[TBL] [Abstract][Full Text] [Related]
17. [5-alpha reductase inhibitor in prostatic adenoma?].
Heinzl S
Med Monatsschr Pharm; 1990 Dec; 13(12):382-4. PubMed ID: 1705307
[No Abstract] [Full Text] [Related]
18. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
19. Benign prostatic hyperplasia: drug and nondrug therapies.
Bruskewitz RC
Geriatrics; 1992 Dec; 47(12):39-42, 45. PubMed ID: 1280242
[TBL] [Abstract][Full Text] [Related]
20. Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol.
Matzkin H; Chen J; Lewyshon O; Ayalon D; Braf Z
Horm Metab Res; 1992 Oct; 24(10):498-9. PubMed ID: 1281461
[No Abstract] [Full Text] [Related]
[Next] [New Search]